M. Bassani-Sternberg

This study tracks tumor-reactive TIL clonotypes in melanoma patients before and after TIL-ACT to identify factors associated with clinical response.

This study identifies ZNF587 and ZNF417 as pro-oncogenic factors in DLBCL that reduce replicative stress and inflammation, promoting cancer cell survival and immune evasion.

This study identifies CD8+ TIL-myeloid cell networks as predictors of response to adoptive TIL therapy in melanoma using single-cell RNA-seq and spatial proteomic analyses.

The paper predicts MHC-II epitope specificities using machine learning, revealing a reverse binding mode in ligands across multiple species.

This study identifies factors influencing immunopeptidome remodeling by IFN-gamma in colorectal cancer, revealing proline's role in peptide downregulation on HLA-I.

The paper identifies 1,113 unique phosphorylated HLA-II ligands and develops a predictor for their presentation on HLA-II molecules.

This paper develops a personalized multi-neoantigen vaccine using long peptides linked to virus-like particles, showing improved anti-tumor effects in a murine mammary carcinoma model.

The paper curates phosphorylated HLA-I ligands and develops a predictor for their interaction with HLA-I molecules.

The paper develops an MS-based proteogenomic approach to identify non-canonical HLA peptides in tumors, finding hundreds of shared and tumor-specific peptides, including an immunogenic one from ABCB5.

The paper improves HLA-II epitope prediction by combining mass spectrometry data with a new motif deconvolution algorithm, enhancing motif definition and prediction accuracy.

The paper analyzes HLA-I ligand length distribution and multiple specificity using HLA peptidomics data from human meningioma samples, improving predictions of naturally presented ligands.

The paper identifies frequent C-terminal extensions in HLA-I ligands across multiple alleles and demonstrates their recognition by CD8+ T cells.